Filgrastim

Section: 8. Immunomodulators and antineoplastics > 8.2. Antineoplastics and supportive medicines > 8.2.3. Immunomodulators

EMLc | ATC codes: L03AA02

Indication	Acquired neutropaenia ICD11 code: 4B00.01
INN	Filgrastim
Medicine type	Biological agent
List type	Complementary
Additional notes	Including quality-assured biosimilars.
Formulations	**Parenteral > General injections > SC:** 120 µg per 0.2 mL in prefilled syringe ; 300 µg per 0.5 mL in prefilled syringe ; 480 µg per 0.8 mL in prefilled syringe ; 300 µg per mL in 1 mL vial ; 480 µg per 1.6 mL in 1.6 mL vial
EML status history	First added in 2015 (TRS 994)
Sex	All
Age	Also recommended for children
Therapeutic alternatives	The recommendation is for this specific medicine
Patent information	Patents have expired in most jurisdictions Read more about patents.
Tags	Cancer Biological
Wikipedia	Filgrastim
DrugBank	Filgrastim

Summary of evidence and Expert Committee recommendations

In 2015, as part of the comprehensive review of cancer medicines undertaken by the Expert Committee, filgrastim, a granulocyte colony stimulating factor, was added to the complementary list of the EML and EMLc for use in the following indications: - primary prophylaxis in patients at high risk for developing febrile neutropenia associated with myelotoxic chemotherapy; - secondary prophylaxis for patients who have experienced neutropenia following prior myelotoxic chemotherapy; - to facilitate administration of dose dense chemotherapy regimens. The relevant extract from TRS994 regarding the Expert Committee's consideration of G-CSF is attached.